Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for the project: “Protein Pathway Activation Based Signaling Mapping of Head And Neck Cancers.”
Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for the project: “Protein Pathway Activation Based Signaling Mapping of Head And Neck Cancers.”
CAPMM researchers will receive laser microdissected tumor samples from banked Formalin-Fixed Paraffin-Embedded (FFPE) clinical biopsy samples from patients with HPV‐positive head and neck cancers who were treated for newly diagnosed disease.
The researchers will utilize comprehensive reverse‐phase protein microarray (RPPA)-based analysis of 170 pre‐specified proteins and phosphoproteins involved in inflammation pathways, DNA damage and repair pathways, reactive oxygen species pathways, mitophagy pathways, cell survival and apoptosis pathways.
Petricoin received $63,640 from Inova Healthcare for this research. Funding began in May 2024 and will end in May 2025.
###
ABOUT GEORGE MASON UNIVERSITY
George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 40,000 students from 130 countries and all 50 states. Mason has grown rapidly over the past half-century and is recognized for its innovation and entrepreneurship, remarkable diversity, and commitment to accessibility. In 2023, the university launched Mason Now: Power the Possible, a one-billion-dollar comprehensive campaign to support student success, research, innovation, community, and stewardship. Learn more at gmu.edu.
